The company will present this week at Benzinga Healthcare and Emerging Growth Small Cap Conferences

SOUTH EASTON, MA / ACCESSWIRE / September 28, 2021 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling and pressure-based platform technology instruments, consumables and solutions for biotechnology, biotherapy, nutraceuticals, cosmetics, agriculture, and food and beverage industries, today announced that the company has accepted invitations to attend the Benzinga Healthcare and Emerging Growth Small Cap conferences from this week. These real-time interactive investor conferences will feature presentations from several emerging, innovative and exciting small-cap companies.

PBI President and CEO Mr. Richard T. Schumacher will provide an overview of the business – including a discussion of its resurgent revenue growth in 2021, the potential impact of the commercial exit planned for its revolutionary Ultra Shear Technology â„¢ (UST â„¢) platform, its imminent acquisition of the assets of an environmentally friendly global agrochemical company and its listing on a US national stock exchange. Mr. Schumacher’s presentation information is below:

Emerging Growth Conference
DATE: Wednesday, September 29, 2021
TIME: 10:30 a.m. EDT
PRESENTATION: Video webcast
SUBSCRIBE (free): To register for the Emerging Growth Conference, click here

Benzinga Healthcare Small Cap Conference
DATE: Thursday, September 30, 2021
TIME: 10:30 a.m. EDT
PRESENTATION: Video webcast
SUBSCRIBE (free): To register for the Benzinga Healthcare Small Cap conference, click here

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the world’s life sciences and other industries. Our products are based on the unique properties of constant (i.e. static) and alternating (i.e. pressure cycling or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions in a safe and reproducible manner (eg, cell lysis, extraction of biomolecules). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutic characterization and quality control, soil and plant biology, forensics and bioterror control applications. In addition, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our patented technology recently acquired from BaroFold, Inc. (the “BaroFold” technology ) to enable entry into the biopharmaceutical contract services industry, and (2) the use of our recently patented, scalable, high efficiency, pressure-based Ultra Shear Technology (“UST”) platform for (i ) create stable nanoemulsions of otherwise immiscible fluids (e.g. oils and water) and (ii) prepare better quality, homogenized, long shelf life or room temperature stable liquid foods, low in acid, which cannot be effectively preserved using existing non-thermal technologies.

Forward-looking statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our actual results, levels of activity, performance or achievements. our industry are materially different from the results, future levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by words such as “could”, “will”, “should”, “could”, “could”, “expects”, “expects”, “has the” intention to “,” plan, “” “believe”, “estimate”, “predict”, “projects”, “potential” or “continue” or the negative of these and other comparable terms. These statements are only predictions based on our current expectations and projections regarding future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statements. These risks, uncertainties and other factors include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2020 , and other reports filed by the Company from time to time with the SEC. The Company does not undertake to update the information included in this press release, unless the law requires otherwise.

For more information on PBI and this press release, please click on the following link:

Please visit us on Facebook, LinkedIn and Twitter.

Press contact:
Richard T. Schumacher, President and CEO (508) 230-1828 (T)
Jeffrey N. Peterson, President (650) 703-8557 (T)

THE SOURCE: Pressure BioSciences Inc.

See the source version on Profitability-in-2022

Leave a Reply

Your email address will not be published.